Clinical trials: Aromatase Inhibitor
Breast Cancer, DCIS
Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs
The purpose of this study is to evaluate the feasibility of an mobile-health strategy to improve patient-reported symptoms, promote life-saving medication adherence, and encourage healthy lifestyle behaviors in early stage breast…
- Trial name
- NCT04170920
- Testing
- LifeExtend-AI
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Indiana University
Hypopituitarism
Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys
The purpose of this study is to see if Arimidex, an aromatase inhibitor, can delay epiphyseal fusion and increase predicted adult height in boys who are growth hormone deficient, in puberty, and who are taking growth hormone.
- Trial name
- NCT00133354
- Testing
- Arimidex (Anastrozole), Growth Hormone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Nemours Children's Clinic
Breast Cancer
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
The goal of this research study is to determine if the investigators can predict which participants will respond to endocrine therapy and a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor for metastatic breast cancer and…
- Trial name
- NCT03439735
- Testing
- Endocrine Therapy and a CDK 4/6 inhibitor
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
CIrCuLAting Dna ESr1 Gene Mutations Analysis
The estrogen-dependent nature of breast cancer was first reported in 1896 with the publication of George Beatson's observations on the regression of breast cancer following oophorectomy.
- Trial name
- CICLADES (NCT03318263)
- Testing
- next-generation sequencing (NGS)
- Where
- 10 sites in France
- Volunteers
- 146 people
- Sponsor
- Institut de Cancérologie de Lorraine
Breast Cancer
Oral Aromatase Inhibitors Modify the Gut Microbiome
The purpose of this research is to study the bacteria in participants' gut before receiving a medicine called an aromatase inhibitor for breast cancer and after participants receive medicine for breast cancer.
- Trial name
- NCT05030038
- Testing
- Fecal swab collection, Blood samples
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer Female, Hormone-receptor-positive Breast Cancer
Promoting Physical Activity in Breast Cancer Survivors on Aromatase Inhibitors
Aromatase inhibitors (AI) are frequently used to treat hormone-receptor-positive breast cancer, but they have multiple adverse effects (eg, arthralgia), resulting in premature therapy discontinuation/switch.
- Trial name
- PAC-WOMAN (NCT05860621)
- Testing
- Brief Physical Activity Counselling, Structured Exercise Program
- Where
- Portugal
- Volunteers
- 122 people
- Sponsor
- Grupo Lusófona
Breast Cancer, Arthralgia
The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer
Patients have been asked to participate in the CEASE study because their treating oncologist has recommended that they start an aromatase inhibitor medication. These medications are associated with joint complaints.
- Trial name
- CEASE (NCT01351844)
- Testing
- Education and exercise intervention, Education and General Exercise
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- George Washington University
Breast Cancer
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
Based on the results of the phase Ib/II study, the investigators hypothesize that combining a RET inhibitor lenvatinib with endocrine therapy letrozole improves objective response and progression-free survival compared to…
- Trial name
- NCT05181033
- Testing
- Lenvatinib + Letrozole, Fulvestrant
- Where
- Singapore
- Volunteers
- 120 people
- Sponsor
- National University Hospital, Singapore
Breast Cancer
Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer
The purpose of this study is to determine whether 6 years adjuvant anastrozole will improve the disease free survival compared to 3 years adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent…
- Trial name
- DATA (NCT00301457)
- Testing
- Anastrozole
- Where
- 67 sites in Netherlands
- Volunteers
- 1,914 people
- Sponsor
- Maastricht University Medical Center
Cardiac Affections
Comparison of Cardiotoxicity Induced by Selective Estrogen REceptor Modulators and aNti-Aromatase
Selective estrogen receptor modulators and aromatase inhibitors for the treatment of breast cancer seems to have an impact on the cardio-vascular system.
- Trial name
- SERENA (NCT03259711)
- Testing
- Hormonal therapies L02 in the ATC classification
- Where
- France
- Volunteers
- 20,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Breast Cancer
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
The purpose of this research study is to study the effects of stopping aromatase inhibitory (AI) therapy on breast cancer progression. Aromatase inhibitors are a class of drugs used to treat breast cancer in postmenopausal women.
- Trial name
- NCT00916162
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
Pilot Study of Hydroxychloroquine for the Treatment of AIMSS
The purpose of this study is to evaluate the effectiveness of hydroxychloroquine sulfate (a type of drug commonly used to treat joint pain caused by inflammation, swelling) in reducing joint pain associated with Aromatase…
- Conditions
- Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain, Breast Cancer
- Trial name
- AIMSS (NCT07825454)
- Testing
- Hydroxychloroquine Sulfate (HCQ)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Indiana University
Breast Cancer
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to investigate the efficacy and safety of adjuvant ribociclib combined with aromatase inhibitor in hormone receptor-positive, HER2-negative…
- Trial name
- NCT07400523
- Testing
- Ribociclib plus aromatase inhibitor, Aromatase inhibitor
- Where
- 4 sites in China
- Volunteers
- 446 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Vaginal Atrophy in Breast Cancer Patients
Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on moderate to severe (MS) and most bothersome symptoms (MBS) of vulvovaginal atrophy (VVA) due to natural, surgical or treatment-induced…
- Trial name
- NCT03740945
- Testing
- Prasterone (DHEA)
- Sponsor
- EndoCeutics Inc.
Breast Neoplasms
Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer
To investigate the benefit of postoperative adjuvant therapy using sequential administration of the hormone, toremifene citrate (TOR) or anastrozole (ANA), after chemotherapy in breast cancer.
- Trial name
- NCT00437359
- Testing
- Toremifene citrate, Anastrozole
- Where
- 7 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Japan Breast Cancer Research Network
Breast Cancer Female, Osteoporosis
Health and QoL in Oncological Patients: Management of Bone Pathology in Italian Citbl Population
Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
- Trial name
- NCT04055805
- Testing
- Observational Analysis
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
Dendritic Cell Based Therapy for Breast Cancer Patients
The primary aim of this study is to investigate time to progression in breast cancer patients vaccinated with autologous dendritic cells pulsed with peptides in combination with adjuvant aromatase inhibitor (AI), Thymosin 1 alpha…
- Trial name
- NCT00935558
- Testing
- DC vaccine, aromatase inhibitor
- Where
- Denmark
- Sponsor
- Inge Marie Svane
Women With ER Positive Breast Cancer Taking (AI) w Joint Discomfort and Stiffness
The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.
The objective of this study is to determine if patients taking aromatase inhibitors (AI), who are experiencing joint discomfort and stiffness, would have reduction in this discomfort and stiffness by participating in a directed…
- Trial name
- NCT02057536
- Testing
- Arm A Directed exercise program, Observation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Christiana Care Health Services
Breast Cancer, Aromatase Inhibitor
Yoga for Aromatase Inhibitor-related Knee Pain Relief in Breast Cancer Patients
The purpose of the study was to investigate the therapeutic effect of Yoga on aromatic inhibitor-induced chronic knee pain in patients with breast cancer.
- Conditions
- Breast Cancer, Aromatase Inhibitor, Yoga, Knee Pain
- Trial name
- NCT03956875
- Testing
- yoga
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- China Medical University Hospital
Breast Neoplasm Female, Arthralgia
Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging
The goal of this pilot observational study is to learn about the feasibility of collecting patient-reported data and stool and blood samples from patients age 65 and older treated with aromatase inhibitor therapy for breast…
- Conditions
- Breast Neoplasm Female, Arthralgia, Aging
- Trial name
- BETA (NCT05700006)
- Testing
- Aromatase inhibitor
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- University of Michigan